UBICHEM Group Adds New Large Scale Manufacturing Site
News Jun 13, 2012
UBICHEM Group has announced further growth of its business by adding a new manufacturing site.
The new member of the group, UBICHEM Pharma Manufacturing, will be producing starting materials, intermediates and other fine chemical products for pharma and non-pharma applications in industrial quantities.
This expansion positions the UBICHEM Group to be one of the biggest providers in the CEE region.
The newly acquired 55,000m2 (590,000 square feet) facility is located in Budapest, Hungary, and it is able to produce fine chemical products in multi-ton quantities.
The new manufacturing site also expands UBICHEM Group’s presence in the non-pharma sector.
“This new plant represents a milestone in UBICHEM history. From now on we are able to provide a comprehensive range of services from process R&D through pilot-scale cGMP API manufacture to high-volume manufacturing. By applying the rigorous quality control and strict production guidelines we have had in place at UBICHEM Pharma Services since 1996, we will now be able to ensure the high quality of the intermediates and fine chemical products at our new manufacturing site” - says CEO József Répási.
“We believe we have a competitive edge over intermediate manufacturers based in Asia by leveraging the highly skilled talent pool of chemists and by meeting high quality expectations and strict deadlines for our customers”- he added.
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE